[Antiarrhythmic effects of prostaglandin E1, A1 and F2beta against CaCl2- and aconitin-arrhythmias in the rat].
D000157:Aconitine / Q000037:antagonists & inhibitors*; D031841:Aconitum / Q000031:analogs & derivatives*; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy*; D002122:Calcium Chloride / Q000037:antagonists & inhibitors*; D002415:Cats; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D008297:Male; D011453:Prostaglandins / Q000627:therapeutic use*; D011454:Prostaglandins A / Q000008:administration & dosage / Q000627:therapeutic use; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use; D011460:Prostaglandins F / Q000008:administration & dosage / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats
D011453:Prostaglandins; D011454:Prostaglandins A; D011458:Prostaglandins E; D011460:Prostaglandins F; D002122:Calcium Chloride; D000157:Aconitine
Uber antiarrhythmische Wirkungen der Prostaglandine E1, A1 und F2beta gegenüber CaCl2- und Akonitin-Arrhythmien der Ratte